Advice to Community Oncologists Treating Chronic Myeloid Leukemia
Gabriela S. Hobbs, MD, clinical director of the Leukemia Service and assistant in medicine at Massachusetts General Hospital, shares her advice for a community oncologist treating a patient with chronic myeloid leukemia.
Gabriela S. Hobbs, MD, clinical director of the Leukemia Service and assistant in medicine at Massachusetts General Hospital, shares her advice for a community oncologist treating a patient with chronic myeloid leukemia (CML).
Hobbs says it is important to understand that while patients with CML seem fine, they are still sick and require the same amount of effort as other patients. These patients can have a near-normal life expectancy, but they still need to be monitored according to the recommendations from the NCCN or ELN Guidelines.
FDA Greenlights Treosulfan/Fludarabine Combo for AlloHSCT in AML and MDS
January 24th 2025The combination of treosulfan and fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia or myelodysplastic syndromes has been approved by the FDA.
Read More
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
What Is Dark Zone Lymphoma, and Is It Clinically Relevant?
January 16th 2025Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated treatment, others remain resistant, highlighting the need for targeted approaches to improve outcomes.
Read More
